Compare VRME & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRME | ICU |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | United States |
| Employees | 30 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.0M | 9.1M |
| IPO Year | N/A | N/A |
| Metric | VRME | ICU |
|---|---|---|
| Price | $0.70 | $4.56 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $1.50 | N/A |
| AVG Volume (30 Days) | 55.6K | ★ 84.3K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $36.85 | $53.00 |
| Revenue Next Year | N/A | $50.00 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.59 | $0.22 |
| 52 Week High | $1.51 | $5.10 |
| Indicator | VRME | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 31.07 | 58.54 |
| Support Level | $0.64 | $2.26 |
| Resistance Level | $0.93 | $4.89 |
| Average True Range (ATR) | 0.05 | 0.36 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 17.89 | 61.00 |
VerifyMe Inc is a logistics company that specializes in time and temperature-sensitive products, as well as providing brand protection and enhancement solutions. The company operates through two reportable business segments: Precision Logistics offers a value-added service provider for time and temperature-sensitive parcel management. Using a proprietary IT platform, it provides real-time information and analysis to mitigate supply chain flow interruption, delivering last-mile resolution for key markets, including the perishable healthcare and food industries; and the Authentication segment specializes in anti-counterfeit and brand protection. The Precision Logistics segment derives the majority of the revenue.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.